Mohammad -Reza Rouini
Division of Biopharmaceutics, Department of Pharmaceutics, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, 14155-6451, Iran
Mahdi Baluchestani
Division of Biopharmaceutics, Department of Pharmaceutics, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, 14155-6451, Iran
Lida Hakemi
Division of Biopharmaceutics, Department of Pharmaceutics, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, 14155-6451, Iran
ABSTRACT
To study the dose linearity of gemfibrozil in therapeutic range, the pharmacokinetic of gemfibrozil was assessed in twelve healthy volunteers after administration of single oral does of 300, 600 and 900 mg gemfibrozil in a randomized cross-over design. Serial blood samples were collected at predetermined times before and after drug administration. Serum gemfibrozil concentrations were determined by a validated reversed phase HPLC method. Pharmacokinetic parameters determined by non compartmental methods. The mean elimination half-lives (t½) of gemfibrozil, which did not vary with the dose, were 1.3±0.2, 1.2±0.2 and 1.4±0.1 h, respectively after the three administered doses. The peak serum levels (Cmax) and area under the serum level versus time curve (AUC) data showed dose-proportional response. The time to peak serum concentration (tmax), apparent clearance (CL/F) and apparent volume of distribution (Vd/F) did not show significant difference over the administered doses. These findings suggest that gemfibrozil disposition is linear over the dose range studied.
PDF References Citation
How to cite this article
Mohammad -Reza Rouini, Mahdi Baluchestani and Lida Hakemi, 2006. Study of Dose-linearity of Gemfibrozil Pharmacokinetics in Human. International Journal of Pharmacology, 2: 75-78.
DOI: 10.3923/ijp.2006.75.78
URL: https://scialert.net/abstract/?doi=ijp.2006.75.78
DOI: 10.3923/ijp.2006.75.78
URL: https://scialert.net/abstract/?doi=ijp.2006.75.78
REFERENCES
- Okerholm, R.A., F.J. Keeley, F.E. Peterson and A.J. Glazko, 1976. The metabolism of gemfibrozil. Proc. R. Soc. Med., 69: 11-14.
Direct Link - Randinitis, E.J., A.W. Kinkel, C. Nelson and T.D. Parker, 1984. Gas chromatographic determination of gemfibrozil and its metabolites in plasma and urine. J. Chromatogr., 307: 210-215.
Direct Link - Knauf, H., E.U. Kolle and E. Mutschler, 1990. Gemfibrozil absorption and elimination in kidney and liver disease. J. Mol. Med., 68: 692-698.
CrossRefDirect Link - Nakagawa, A., A. Shigeta, H. Iwabuchi, M. Horiguchi, K. Nakamura and H. Takahagi, 1991. Simultaneous determination of gemfibrozil and its metabolites in plasma and urine by a fully automated high performance liquid chromatographic system. Biomed. Chromatogr., 5: 68-73.
Direct Link - Okerholm, R.A., 1976. Gemfibrozil: A new lipid lowering agent. Proc. R. Soc. Med., 69: 115-120.
Google - Forland, S.C., Y. Feng and R.E. Cutler, 1990. Apparent reduced absorption of gemfibrozil when given with colestipol. Clin. Pharmacol., 30: 29-30.
Direct Link - Liu, X.D., L. Xie, J. Wang, Y.S. Zhou, Z. Wang and G.Q. Liu, 1996. Two-site absorption model fits to pharmacokinetic data of gemfibrozil in man. Yao Xue Xue Bao, 31: 737-741.
Direct Link - Miller, D.B. and J.D. Spence, 1998. Clinical pharmacokinetics of fibric acid derivatives (fibrates). Clin. Pharmacokinet., 34: 155-162.
Direct Link - Amidon, G.L., H. Lennernaes, V.P. Shah and J.R. Crison, 1995. A theoretical basis for a biopharmaceutic drug classification: The correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm. Res., 12: 413-420.
CrossRef - Rudman, A. and R. Williams, 1995. Guidance for industry: Immediate release solid oral dosage forms. Scale up and Post-approval Changes: Chemistry, Manufacturing and Controls, in vitro Dissolution Testing and in vitro Bioequivalence Documentation. Centre for Drug Evaluation and Research, Food and Drug Administration.